NRF2 and p53: Januses in cancer?
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
// Barak Rotblat 1 , Gerry Melino 1,2 , Richard A. Knight 1 1 Medical research Council, Toxicology Unit, Leicester University, Leicester, UK 2 Biochemistry IDI-IRCCS Laboratory, Department of Experimental Medicine and Surgery, University of Rom ‘Tor Vergata’, Rome, Italy Correspondence: Gerry Melino, email: // Keywords : P53, p73, TIGAR, p21, NQO1, NADPH, ROS, metabolism, proteasome, KEAP1, MDM2, chemotherapy, BSO, piperlongumine, BPTES, brusatol Received : November 1, 2012, Accepted : November 19, 2012, Published : November 19, 2012 Abstract The transcription factor nuclear factor (erythroid-derived 2)-like 2, also known as NFE2L2 or NRF2, is a master regulator of the anti-oxidative stress response and positively controls the expression of a battery of anti-oxidative stress response proteins and enzymes implicated in detoxification and glutathione generation. Although its detoxifying activity is important in cancer prevention, it has recently been shown that cancer cells also exploit its protective functions to thrive and resist chemotherapy. NRF2 was also shown to the pentose phosphate pathway and glutaminolysis, which promotes purine synthesis for supporting rapid proliferation and glutathione for providing anti-oxidative stress protection. Evidence obtained from cancer patients and cell lines suggest that NRF2 is highly active in a variety of human cancers and is associated with aggressiveness. p53 is a tumor suppressor that also promotes an anti-oxidative stress metabolic program and glutaminolysis. Here we will discuss the similarities between NRF2 and p53 and review evidence that p53 might be exploited by cancer cells to gain protection against oxidative stress, as is the case for NRF2. We discuss findings of co-regulation between these transcription factors and propose possible therapeutic strategies that can be used for treatment of cancers that harbor WT p53 and express high levels of NRF2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling
Ray, P. D., Huang, B.-W., & Tsuji, Y. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.01.008 · Cited by 4,373 · cited 1×
“ROS can promote tumor initiation by damaging DNA that will lead to mutations and by augmenting signaling pathways that promote cell growth and proliferation [44].”
BackgroundThe Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088 · cited 1×
“Later, it was also shown that p53 regulates GLS2 expression promoting glutathione generation by increasing glutaminolysis [71, 72], a metabolic process that promotes the conversion of glutamine to glutamate that is often active in cancer cells [73-77].”
BackgroundItoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J. D., & Yamamoto, M. (1999) · Genes & Development · doi:10.1101/gad.13.1.76 · Cited by 3,634 · cited 1×
“The NRF2-KEAP1 molecular system is a sensor of oxidative stress [30].”
BackgroundThe evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330 · cited 1×
“This particular NRF2-driven pro-proliferation metabolic program was shown to be dependent on the hyperactivation of the PI3K-AKT pathway, a pathway that is typically deregulated in cancer [127, 128] providing further support to the premise that cancer cells and their oncogenic pathways utilize NRF2 to their own advant…”
BackgroundBlinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · cited 1×
“p53 coordinates a large number of integrated transcriptional programs that result in divers biological outputs [80-84].”
BackgroundDeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., & Thompson, C. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709747104 · Cited by 2,622
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Manipulation of these modifications is an attractive strategy when attempting to dissect the roles of specific p53 transcriptional programs in its biological functions and pharmacological reactivation of p53 activity in cancer is an active research field [91-98].”
BackgroundSignal transduction by reactive oxygen species
Finkel, T. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201102095 · Cited by 2,322 · cited 1×
“When in excess, ROS can damage DNA, proteins and lipids and promote mutations that may contribute to onset of a wide spectrum of human diseases [3-5] particularly diseases that are associated with aging [6-8] such as neurodegeneration [9-12] and cancer [13-15].”
BackgroundOncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277 · cited 2×
“Nrf2 KO mice showed reduced tumor occurrence, reduced proliferation in the tumors arising in these mice and increased overall survival [123].”
BackgroundKobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224 · cited 1×
“com/oncotarget interacts with KEAP1, an adaptor molecules which directs its targets to the CUL3 E3 ligase [31] for ubiquitylation and subsequent degradation by the proteasome [32, 33].”
BackgroundTIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019 · cited 2×
“Further examination of the p53-3KR mutants revealed that they did retain the WT function in executing a transcriptional metabolic program that resulted in reducing glucose uptake, reducing glycolysis and reducing ROS generation that were associated with induction of the p53 anti-oxidative stress targets GLS2 [72] and…”
BackgroundDinkova-Kostova, A. T., Holtzclaw, W. D., Cole, R. N., Itoh, K., Wakabayashi, N., Katoh, Y., Yamamoto, M., & Talalay, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398899 · Cited by 1,947 · cited 1×
“Under oxidative stress, specific KEAP1 cysteines become oxidized resulting in disruption of the KEAP1NRF2 complex, leading to a release of NRF2 from KEAP1 inhibition and promoting its stabilization [34, 35].”
BackgroundRestoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“Manipulation of these modifications is an attractive strategy when attempting to dissect the roles of specific p53 transcriptional programs in its biological functions and pharmacological reactivation of p53 activity in cancer is an active research field [91-98].”
BackgroundCBP/p300 in cell growth, transformation, and development
Goodman, R. H., & Smolik, S. (2000) · Genes & Development · doi:10.1101/gad.14.13.1553 · Cited by 1,778 · cited 1×
“This activity is achieved by the employment of different pathways, spanning from gene and microRNA regulation to protein-protein interaction [130, 133-137].”
BackgroundNrf2–Keap1 defines a physiologically important stress response mechanism
Motohashi, H., & Yamamoto, M. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.09.003 · Cited by 1,725 · cited 1×
“com/oncotarget interacts with KEAP1, an adaptor molecules which directs its targets to the CUL3 E3 ligase [31] for ubiquitylation and subsequent degradation by the proteasome [32, 33].”
BackgroundKruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610
Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution
Taguchi, K., Motohashi, H., & Yamamoto, M. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01473.x · Cited by 1,478 · cited 2×
“These findings, and cell based experiments, point to a model that argues that NRF2 can be exploited by cancer cells in order to curb oxidative stress and perhaps to enhance their chemo-resistance [109, 111, 116-122] Aberrant proliferation is one of the hallmarks of cancer and oncogenes will often activate growthpromot…”
BackgroundNrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., & Motohashi, H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.016 · Cited by 1,395 · cited 2×
“Indeed, p53 was shown to protect A549 cells used in the NRF2 study discussed above [126], from toxicity and radio sensitization using the metabolic inhibitor 2-Deoxy-glucose (2DG), by increasing anti-oxidative stress response and promoting oxidative phosphorylation [142, 143].”
Backgroundp53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling
Budanov, A. V., & Karin, M. (2008) · Cell · doi:10.1016/j.cell.2008.06.028 · Cited by 1,326 · cited 1×
“In resting conditions, p53 protein is maintained at low levels by MDM2 mediated proteasomal degradation [61-66] and at this low level of expression reduces ROS levels by inducing the expression of anti-oxidative stress proteins such as SESN1, SESN2 and GPX1 [67-70].”
BackgroundEvidence that glutamine, not sugar, is the major energy source for cultured HeLa cells.
Reitzer, L. J., Wice, B. M., & Kennell, D. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)30124-2 · Cited by 1,240
Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B Cells
Le, A., Lane, A. N., Hamaker, M., Bose, S., Gouw, A., Barbi, J., Tsukamoto, T., Rojas, C. J., Slusher, B. S., Zhang, H., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2011.12.009 · Cited by 1,095
NRF2 and cancer: the good, the bad and the importance of context
Sporn, M. B., & Liby, K. T. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3278 · Cited by 1,067 · cited 1×
“While these mechanisms are important to prevent disease onset, it is now becoming evident that the same mechanisms are being exploited by cancer cells in order to survive and thrive under oxidative stress insults and to armor themselves against therapeutic interventions that rely on oxidative stress as their mechanism…”
BackgroundDysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidransky, D., Gabrielson, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030420 · Cited by 1,060 · cited 2×
“These include somatic mutations in NRF2 that disrupt its interaction with KEAP1 [110, 111] and somatic mutations in KEAP1 that disrupt its interaction with NRF2 [112-115].”
BackgroundTumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence
Li, T., Kon, N., Jiang, L., Tan, M., Ludwig, T., Zhao, Y., Baer, R., & Gu, W. (2012) · Cell · doi:10.1016/j.cell.2012.04.026 · Cited by 912
Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function
Hu, W., Zhang, C., Wu, R., Sun, Y., Levine, A., & Feng, Z. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001006107 · Cited by 862
Acetylation of the p53 DNA-binding domain regulates apoptosis induction.
Sykes, S. M., Mellert, H. S., Holbert, M. A., Li, K., Marmorstein, R., Lane, W. S., & McMahon, S. B. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.11.026 · Cited by 752 · cited 1×
“Among other modifications, p53 is acetylated on three lysines [99-101].”
BackgroundStructural basis for defects of Keap1 activity provoked by its point mutations in lung cancer
Padmanabhan, B., Tong, K. I., Ohta, T., Nakamura, Y., Scharlock, M., Ohtsuji, M., Kang, M.-I., Kobayashi, A., Yokoyama, S., & Yamamoto, M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.013 · Cited by 735 · cited 1×
“These include somatic mutations in NRF2 that disrupt its interaction with KEAP1 [110, 111] and somatic mutations in KEAP1 that disrupt its interaction with NRF2 [112-115].”
BackgroundShibata, T., Ohta, T., Tong, K. I., Kokubu, A., Odogawa, R., Tsuta, K., Asamura, H., Yamamoto, M., & Hirohashi, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806268105 · Cited by 728
Suzuki, S., Tanaka, T., Poyurovsky, M. V., Nagano, H., Mayama, T., Ohkubo, S., Lokshin, M., Hosokawa, H., Nakayama, T., Suzuki, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002459107 · Cited by 705
Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism
Ren, D., Villeneuve, N. F., Jiang, T., Wu, T., Lau, A., Toppin, H. A., & Zhang, D. D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014275108 · Cited by 673
Direct Interaction between Nrf2 and p21Cip1/WAF1 Upregulates the Nrf2-Mediated Antioxidant Response
Chen, W., Sun, Z., Wang, X.-J., Jiang, T., Huang, Z., Fang, D., & Zhang, D. D. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.04.029 · Cited by 638 · cited 1×
“Interestingly, recent findings from the Zhang lab indicate that p21, a p53 target gene [144, 145], stabilizes NRF2 by binding to KEAP1 and interfering with its ability to promote NRF2 ubiquitylaton and proteasomal degradation [146].”
BackgroundLing, J., Kang, Y., Zhao, R., Xia, Q., Lee, D.-F., Chang, Z., Li, J., Peng, B., Fleming, J. B., Wang, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.006 · Cited by 513
Cancer metabolism: current perspectives and future directions
Muñoz-Pinedo, C., El Mjiyad, N., & Ricci, J.-E. (2012) · Cell Death & Disease · doi:10.1038/cddis.2011.123 · Cited by 385 · cited 1×
“In order to support rapid proliferation, tumor cells rely on catabolic processes for generation of building blocks such as lipids, proteins and nucleic acids [125].”
BackgroundA mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73
Asher, G., Tsvetkov, P., Kahana, C., & Shaul, Y. (2005) · Genes & Development · doi:10.1101/gad.319905 · Cited by 367 · cited 1×
“On the other hand, previous findings from the Shaul lab indicate that NQO1, an NRF2 target, interacts with p53 [147] and blocks its degradation by the 20S proteasome [148], a degradation process that is independent of MDM2 and ubiquitin [59, 149] (Fig.”
BackgroundMdm2-mediated ubiquitylation: p53 and beyond
Marine, J.-C., & Lozano, G. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.68 · Cited by 354
p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC
Christoffersen, N. R., Shalgi, R., Frankel, L. B., Leucci, E., Lees, M., Klausen, M., Pilpel, Y., Nielsen, F. C., Oren, M., & Lund, A. H. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.109 · Cited by 352 · cited 1×
“This activity is achieved by the employment of different pathways, spanning from gene and microRNA regulation to protein-protein interaction [130, 133-137].”
BackgroundVanlangenakker, N., Vanden Berghe, T., Bogaert, P., Laukens, B., Zobel, K., Deshayes, K., Vucic, D., Fulda, S., Vandenabeele, P., & Bertrand, M. J. M. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2010.138 · Cited by 339
Li, D., Marchenko, N. D., & Moll, U. M. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.71 · Cited by 336 · cited 1×
“Stabilization or reactivation of p53 throughout the use of small molecules is a promising therapeutic strategy [96, 98, 153-157].”
BackgroundJackson, J. G., Pant, V., Li, Q., Chang, L. L., Quintás-Cardama, A., Garza, D., Tavana, O., Yang, P., Manshouri, T., Li, Y., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.027 · Cited by 329
The multiple levels of regulation by p53 ubiquitination
Lee, J. T., & Gu, W. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.77 · Cited by 289 · cited 1×
“In resting conditions, p53 protein is maintained at low levels by MDM2 mediated proteasomal degradation [61-66] and at this low level of expression reduces ROS levels by inducing the expression of anti-oxidative stress proteins such as SESN1, SESN2 and GPX1 [67-70].”
BackgroundHigh Levels of Nrf2 Determine Chemoresistance in Type II Endometrial Cancer
Jiang, T., Chen, N., Zhao, F., Wang, X.-J., Kong, B., Zheng, W., & Zhang, D. D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0713 · Cited by 286 · cited 2×
“It was also found that high NRF2 expression or nuclear localization and low KEAP1 expression were associated with poor prognosis [116].”
Backgroundp53, ROS and senescence in the control of aging
Vigneron, A., & Vousden, K. H. (2010) · Aging · doi:10.18632/aging.100189 · Cited by 221 · cited 1×
“When in excess, ROS can damage DNA, proteins and lipids and promote mutations that may contribute to onset of a wide spectrum of human diseases [3-5] particularly diseases that are associated with aging [6-8] such as neurodegeneration [9-12] and cancer [13-15].”
BackgroundStressin’ Sestrins take an aging fight
Budanov, A. V., Lee, J. H., & Karin, M. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000097 · Cited by 208 · cited 1×
“In resting conditions, p53 protein is maintained at low levels by MDM2 mediated proteasomal degradation [61-66] and at this low level of expression reduces ROS levels by inducing the expression of anti-oxidative stress proteins such as SESN1, SESN2 and GPX1 [67-70].”
BackgroundThangavelu, K., Pan, C. Q., Karlberg, T., Balaji, G., Uttamchandani, M., Suresh, V., Schüler, H., Low, B. C., & Sivaraman, J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116573109 · Cited by 206 · cited 1×
“Targeting Kidney type Glutaminase (KGA), an essential enzyme in glutaminolysis, using an inhibitor such as BPTES, could inhibit glutaminolysis [165-167].”
BackgroundMichaelis, M., Rothweiler, F., Barth, S., Cinatl, J., van Rikxoort, M., Löschmann, N., Voges, Y., Breitling, R., von Deimling, A., Rödel, F., et al. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.129 · Cited by 190 · cited 1×
“It is now clear that the cancer cells will utilize endogenous protective mechanisms to evolve chemoresistance [172-174].”
Stress-mediated nuclear stabilization of p53 is regulated by ubiquitination and importin-α3 binding
Marchenko, N. D., Hanel, W., Li, D., Becker, K., Reich, N., & Moll, U. M. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.173 · Cited by 123 · cited 1×
“p53 protein levels in the cells are tightly regulated [58-60].”
BackgroundVaseva, A. V., Yallowitz, A. R., Marchenko, N. D., Xu, S., & Moll, U. M. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.39 · Cited by 55
Azmi, A. S., Banerjee, S., Ali, S., Wang, Z., Bao, B., Beck, F. W. J., Maitah, M., Choi, M., Shields, T. F., Philip, P. A., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.269 · Cited by 48 · cited 1×
“However, we believe that alternative approaches should be explored in order to win the war against cancer [158-163].”
Background
Cited by
Metabolic Regulation by p53 Family Members
Berkers, C. R., Maddocks, O. D. K., Cheung, E. C., Mor, I., & Vousden, K. H. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.06.019 · Cited by 446
The complexity of p53-mediated metabolic regulation in tumor suppression
Liu, Y., & Gu, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.010 · Cited by 261
Yoon, D. S., Choi, Y., & Lee, J. W. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.3 · Cited by 105
Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation
Gong, M., Li, Y., Ye, X., Zhang, L., Wang, Z., Xu, X., Shen, Y., & Zheng, C. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00568-z · Cited by 86
Functional, proteomic and bioinformatic analyses of Nrf2- and Keap1- null skeletal muscle
Gao, L., Kumar, V., Vellichirammal, N. N., Park, S., Rudebush, T. L., Yu, L., Son, W., Pekas, E. J., Wafi, A. M., Hong, J., et al. (2020) · The Journal of Physiology · doi:10.1113/jp280176 · Cited by 58
“Indeed, P53 has been demonstrated to evoke similar protection as Nrf2 against oxidative stress (Rotblat et al. 2012).”
Background
Metadata
- Authors
- Rotblat, B., Melino, G., & Knight, R. A.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2012-11-19
- Volume
- 3
- Issue
- 11
- Pages
- 1272-1283
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1642779520
- Cited by
- 109
- References
- 49
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.